Market research
ENLV Enlivex Therapeutics Ltd
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 4M
- P/E ratio
- 0.0
- Analyst target
- 1280
- Dividend yield
- Not available
- Beta
- 1.41
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IL0011319527
- Market cap
- 4M
- P/E ratio
- 0.0
- Analyst target
- 1280
- Dividend yield
- Not available
- Beta
- 1.41
About
About Enlivex Therapeutics Ltd
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Research context
Enlivex Therapeutics Ltd appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ENLV discussion.
5 years, 6 months ago
Enlivex Therapeutics Ltd is currently in a long term downtrend where the price is trading 31.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Enlivex Therapeutics Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 11.1% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 30.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Enlivex Therapeutics Ltd gets an overall score of 2/5.